The U.S. Food and Drug Administration (FDA) has proposed a rule to simplify registration for drug manufacturers operating under a "hub-and-spoke" model, potentially reducing compliance costs while enhancing supply chain transparency. The move targets firms with centralized quality management systems across multiple production sites.
Streamlined Registration for Hub-and-Spoke Manufacturers
Under current regulations, each facility in a hub-and-spoke network must register separately with the FDA. The proposed rule would allow such manufacturers to register as a single establishment, with the flexibility to add, relocate, or remove units through a streamlined update process. Companies would still be required to notify the FDA before relocating any manufacturing unit.
Clarified Requirements for Foreign Facilities
The proposal also addresses gaps in oversight for foreign establishments producing drugs or active pharmaceutical ingredients (APIs) exclusively for export to other foreign facilities. Currently, some of these facilities may not be registered with the FDA, limiting the agency’s visibility into upstream supply chains. The new rule would explicitly require registration and drug listing for these entities, improving traceability and response to safety concerns.
Cost Savings and Operational Efficiency
If finalized, the rule is expected to reduce registration costs and generate long-term efficiencies for both the pharmaceutical industry and the FDA. The agency emphasizes that the changes would enhance its ability to monitor drug production and distribution networks, particularly for complex, multi-site operations.
- Manufacturers using a centralized quality system could register as a single facility.
- Foreign API producers must register if supplying other foreign facilities.
- FDA gains better visibility into upstream supply chains.
